NEWSROOM
20487_FP_Header_Newsroom_Website_2400x900px

The latest from Dr. Falk Pharma

Welcome to our Newsroom, providing you with the latest news, press releases, clinical trial announcements, events, and more from Dr. Falk Pharma.

Follow us on LinkedIn!

Indication

Today is World IBD Day 2025

IBD Has No Borders – Breaking Taboos, Talking About It.

Corporate

The 2025 Dr. Falk/BASL Awards are open for entries!

Rewarding team innovation & improvement in patient care within hepatology

Press release, Study

Positive results from pivotal phase 3 trial on norucholic acid in PSC

The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam

Corporate

New General Manager for Dr. Falk Pharma UK

We are pleased to announce a significant leadership change in our UK/IE affiliate. After over 20 years of dedicated service, Anthony McFadyen ("Tony")…

Corporate

Dr. Falk Ireland Nurse Recognition Award for Improvement in Patient Care 2025

Many congratulations to Sarah Gleeson, winner of the 2025 Dr Falk Ireland Nurse Recognition Award for Improvement in Patient Care

Event

EASL 2025

Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.

Corporate

Following the footsteps of our founder - The End

Elena looks back and summarizes her journey: it's a collection of emotional encounters, funny moments, and, most of all, it's a big THANK YOU!

Event

Back to the Future – Unleashing the Power of Established Drugs

Lunch satellite symposium on 21.02.2025 during the Congress of ECCO in Berlin

Press release

Dr. Falk Pharma acquires Kynos Therapeutics

...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio

Corporate

Elena in the UK

... following her grandpa's footsteps in Edinburgh and London

Corporate

Following the footsteps of our founder

Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.

Press release

Dosing of the First United States Patient

...and expansion of the Phase 2b Study of Naronapride in Gastroparesis

Corporate

In memory of our founder

100 years ago today, Dr. Dr. Herbert Falk was born

Press release

New Addition to the Management Board

The new Technical Operations business unit will be headed up by Dr. Andreas Rascher

Press release

FDA clearance of IND application for naronapride

...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US

Press release

Advancing the development of naronapride...

...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication